GC

Genelux Corporation

GNLX·NASDAQ

$3.00

+1.0%
HealthcareBiotechnology

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

At a Glance

Live Snapshot
Market Cap$112.85M
EPS-0.8600
P/E Ratio-3.49
Earnings Date08/06/2026

gnlx

Total Payables

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

GC

Genelux Corporation Competitors Analysis of Total Payables

GNLX · NASDAQ
CompanyTotal Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
158.46K
-50.9%-31.1%-5.4%
CDXS logo
Codexis, Inc.
NASDAQ:CDXS
1.55M
-36.1%-12.3%-9.5%
2.21M
-11.3%4.4%-4.3%
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
13.74M
20.0%18.9%N/A
OABI logo
OmniAb, Inc.
NASDAQ:OABI
1.88M
-24.8%-13.7%N/A
10.88M
40.8%-1.9%N/A
2.95M
-19.4%6.6%5.1%
1.13M
38.8%-6.6%N/A
4.86M
8.6%6.2%N/A
1.02M
17.0%9.0%N/A
GC

Genelux Corporation Fair Value Envelope

GNLX · NASDAQ

Our analysis suggests that GNLX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3, this represents a potential HIDDEN relative to our calculated worth for Genelux Corporation.

Intrinsic Value
Current Price: $3